Halozyme Therapeutics | HALO - Cost Of Sales

Stock Price
81.23
Daily Change
2.81 3.58%
Monthly
8.15%
Yearly
42.26%
Q1 Forecast
69.50

Halozyme Therapeutics reported $73M in Cost of Sales for its fiscal quarter ending in September of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 21.65M 913K Sep/2025
Agios Pharmaceuticals USD 1.68M 22K Sep/2025
Alnylam Pharmaceuticals USD 200.15M 57.2M Sep/2025
Amarin USD 16.89M 18.51M Mar/2025
Amgen USD 1.79B 128M Dec/2025
Baxter International USD 1.88B 66M Sep/2025
Cytokinetics USD 112.55M 12.71M Jun/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Halozyme Therapeutics USD 73M 8.88M Sep/2025
Ionis Pharmaceuticals USD 2.34M 1.81M Sep/2025
MannKind USD 20.2M 365K Sep/2025
Pfizer USD 6.29B 2.12B Dec/2025
United Therapeutics USD 100.9M 74.3M Sep/2025